Summary
N-methyl-N-propargyl-2-aminotetralin (N-0425), a semi rigid analogue of deprenyl was found to be a potent inhibitor of monoamine oxidase type-A and-B. The MAO inhibitory potency was determined in in-vitro, ex-vivo and in-vivo experiments for racemic N-0425 and for both enantiomers, and compared with deprenyl. Racemic N-0425 and (−)N-0425 were found to inactivate both MAO-A and-B to about the same extent in rat brain homogenates, whereas (+)N-0425 was 10 times more potent in inhibiting MAO-B than MAO-A under in-vitro conditions. The latter compound was almost 3 times less active than (−)deprenyl with respect to inactivation of MAO-B. In ex-vivo experiments it was shown that (±)- and (+)N-0425 inhibited rat striatal MAO-B activity almost completely 2 h after a dose of 0.01 mmol/kg ip, whereas both compounds produced a much less rapid inactivation of type-A MAO, which was about 65% after 23 h. No potentiation of the tyramine induced increase in systolic blood pressure was found in normotensive rats following doses up to 0.01 mmol/kg ip of racemic N-0425, but a potentiation was observed after a higher dose of 0.04 mmol/kg. Levels of dopamine and noradrenaline were both increased in rat frontal cortex after the administration of N-0425, which can be interpreted as a reflection of MAO inactivation. Since we were able to select a dose of (±)N-0425 which potently inhibits MAO, without producing a concomittant potentiation of the tyramine effect on blood pressure in normotensive rats, it is reasonable to suggest that this compound, like deprenyl, could be useful in the treatment of Parkinson's disease.
Similar content being viewed by others
Abbreviations
- MAO:
-
monoamine oxidase
- l-DOPA:
-
3,4-dihydroxyphenylalamine
- DA:
-
dopamine
- DOPAC:
-
3,4-dihydroxyphenylacetic acid
- HVA:
-
homovanillic acid
- 3-MT:
-
3-methoxytyramine
- NA:
-
noradrenaline
- NM:
-
normetanephrine
- 5-HT:
-
5-hydroxytryptamine
- 5-HIAA:
-
5-hydroxyindoleacetic acid
- PEA:
-
β-phenylethylamine
- N-0425:
-
N-methyl-N-propargyl-2-aminotetralin
References
Ashkenazi R, Finberg JPM, Youdim MBH (1983) Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Br J Pharmacol 79:765–770
Birkmayer W, Riederer P, Youdim MBH (1982) (−)Deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 5:195–230
Blackwell B, Mabbitt LA (1965) Tyramine in cheese related to hypertensive crises after monoamine oxidase inhibition. Lancet i:938–940
Buckholtz NS, Boggan WO (1977) Monoamine oxidase inhibition in brain and liver produced by β-carbolines: Structure-activity relationships and substrate specificity. Biochem Pharmacol 26:1991–1996
Cohen RM, Campbell IC, Yamaguchi I, Pickar D, Kopin IJ, Murphy DL (1982) Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. Eur J Pharmacol 80:155–160
Demarest KT, Moore KE (1981) Type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the rat. J Neural Transm 52:175–187
Dzoljic MR, Bruinvels J, Bonta JL (1977) Desynchronization of electrical activity in rats induced by deprenyl — an inhibitor of monoamine oxidase B — and relationship with selective increase of dopamine and β-phenylethylamine. J Neural Transm 40:1–12
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology 57:33–38
Finberg JPM, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77:13–21
Fowler CJ (1982) Selective inhibitors of monoamine oxidase types A and B and their clinical usefulness. Drugs Future 7:501–517
Fowler CJ, Strolin Benedetti M (1983) The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J Neurochem 40:1534–1541
Fowler CJ, Tipton KF (1982) Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem 38:733–736
Glover V, Elsworth JD, Sandler M (1980) Dopamine oxidation and its inhibition by (−)-deprenyl in man. J Neural Transm Suppl 16:163–172
Glover V, Pycock CJ, Sandler M (1983) Tyramine-induced noradrenaline release from rat brain slices: prevention by (−)-deprenyl. Br J Pharmacol 80:141–148
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81
Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the brain. J Neurochem 13:655–669
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408
Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacology 18:118–123
Linnoila M, Karoum F, Potter WZ (1982) Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiatry 39:513–516
Nagyar K, Ecseri Z, Bernath G, Sátory E, Knoll J (1980) Structure-activity relationship of selective inhibitors of MAO-B. In: Magyar K (ed) Monoamine oxidases and their selective inhibition. Third congress of the Hungarian Pharmacological Society. Akadémiai Kiadó. Budapest, pp 11–21
Mendis N, Pare CMB, Sandler M, Glover V, Stern M (1981a) Is the failure of (−)-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73:87–90
Mendis N, Pare CMB, Sandler M, Glover V, Stern G (1981b) (−)-Deprenyl in treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — the state of the art. John Wiley and Sons. London, pp 171–176
Mendlewicz J, Youdim MBH (1981) A selective MAO-B inhibitor (l-deprenil) and 5-HTP as antidepressant therapy. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — the state of the art. John Wiley and Sons, London, pp 177–188
Mendlewicz J, Youdim MBH (1983)l-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatr 142:508–511
Murphy DL, Lipper S, Pickar D, Jimerson D, Cohen RM, Garrick NA, Alterman JS, Campbell IC (1981) Selective inhibition of monoamine oxidase type A: Clinical antidepressant effects and metabolic changes in man. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — the state of the art. John Wiley and Sons, London, pp 189–205
Pickar D, Cohen RM, Jimerson DC, Murphy DL (1981) Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacol 74:4–7
Provoost AP, Bohus B, de Jong W (1974) Neonatal chemical sympathectomy: Functional control of denervation of the vascular system and tissue noradrenaline level in the rat after 6-hydroxydopamine. Naunyn-Schmiedeberg's Arch Pharmacol 284:353–363
Prozialeck WC, Vogel WH (1978) Deamination of 5-methoxytryptamines, serotonin and phenylethylamine by rat MAO in vitro and in vivo. Life Sci 22:561–570
Rinne UK, Siirtola T, Sonninen V (1978)l-Deprenyl treatment of on-off phenomena in Parkinson's disease. J Neural Transm 43:253–262
Schoepp DD, Azzaro AJ (1981) Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem 36:2025–2031
Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical pharmacology of (−)-deprenyl. J Neural Transm 43:245–251
Strolin Benedetti M, Sontag N, Boucher T, Kan JP (1981) Aliphatic amines as MAO substrates in the rat: The effect of selective inhibitors on the deamination of n-pentylamine. In: Usdin E, Weiner N, Youdim MBH (eds) Function and regulation of monoamine enzymes: basic and clinical aspects. MacMillan, London Basingstoke, pp 527–538
Waldmeier PC, Delini-Stula A, Maître L (1976) Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 292:9–14
Waldmeier PC, Maître L (1976) Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism. Naunyn-Schmiedeberg's Arch Pharmacol 294:133–140
Waldmeier PC, Antonin KH, Feldtrauer JJ, Grunenwald Ch, Paul E, Lauber J, Bieck P (1983) Urinary excretion of O-methylated catecholamines, tyramine and phenylethylamine by volunteers treated with tranylcypromine and CGP 11305 A. Eur J Clin Pharmacol 25:361–368
Westerink BHC (1983) Analysis of trace amounts of catecholamines and related compounds in brain tissue: A study near the detection limit of liquid chromatography and electrochemical detection. J Liquid Chromatogr 6:2337–2351
Wurtman RJ, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 12:1439–1440
Yang HYT, Neff NH (1974) The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189:733–740
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hazelhoff, B., De Vries, J.B., Dijkstra, D. et al. The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor. Naunyn-Schmiedeberg's Arch. Pharmacol. 330, 50–58 (1985). https://doi.org/10.1007/BF00586709
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00586709